Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

NCT04460430 | Terminated Phase 2

• 2 other identifiers: SOLTI-17182019-000710-11
• Study Type: interventional
• Target: 12
• Locations: 2 countries
• Sites: 15

Brief Summary

HR+/HER2-negative BC represent ∼70% of all newly diagnosed breast tumours and are responsible for most recurrences and deaths due to this disease, and despite available standard therapies, ∼15-20% of hormone tumours recur at distant sites. As BC is a clinically and biologically heterogeneous disease, intrincsic subtype may play an important role in classifying patients. In this case, HER2-E subtype is present in approximately 6.6-11.0% of HR+/HER2-negative tumors and might express either HER2, estrogen receptor (ER) or progesterone receptor (PR), we also know that HER2-E is present twice as much in metastatic tumors compared to primary tumors and that HER2-E patients may benefit in terms of PFS form an anti-HER2 drug as was showed using retrospective sample in EGF30008 trial. Therefore, incorporation of novel drugs in combination with endocrine therapy (ET) can improve patient outcomes in HR+/HER2-negative BC advanced disease specially in those with HER2-E subtype. Methods NEREA is an open-label, single arm, multicenter phase II study evaluating treatment with neratinib in combination with ET in pre and post-menopausal women and men with locally advanced or metastatic HER2-enriched (HER2-E), HR+/HER2-negative breast cancer who had recurrence or progression while receiving previous ET (either aromatase inhibitors, tamoxifen or fulvestrant) in the adjuvant setting or to treat advanced disease or both. The study will follow a Simon's 2-stage design with one interim and one final efficacy analysis. The primary objective will is assess the efficacy of neratinib in combination with ET is this group of patients, efficacy will be measured as Progression-Free Survival at 6 months (PFS6) defined as the proportion of patients alive and without progression, locally assessed by the investigator through the use of RECIST v.1.1 at 24 weeks after first treatment administration, imaging evaluation will be performed every 8 weeks for the first 12 months following treatment start, and every 12 weeks thereafter. Secondary endpoints include Clinical Benefit Rate at 6 months , Overall Response rate, Duration of response, Time to response and Incidence, duration and severity of Adverse Events. The interim analysis will be conducted when 33 patients are evaluable for the primary endpoint having the potential for at least 3 'on treatment' disease assessment scans. If less than 15 patients achieved a PFS6, the trial will be terminated for futility in favor of the null hypothesis. If more than 28 patients achieved a PFS6, the trial will be stopped in favor of the alternative hypothesis demonstrating activity. If none of the two above-mentioned conditions are attain, up to a further 23 patients may be evaluated, for at least a total of 56 evaluable patients. Therefore, if a total of 28 or more patients achieved a PFS6 at the end of the second stage, then the null will be rejected in favor of the alternative. Eligible patients will receive neratinib 240 mg every day in combination with ET, with either exemestane, fulvestrant or tamoxifen: exemestane 25 mg every day orally, tamoxifen 20mg every day orally or fulvestrant 500 mg administered in two intramuscular injections of 250 mg each at C1D15 and at D1 of each subsequent 28-day cycle at investigator discretion. LHRH agonist will be used in men and premenopausal women if no oophorectomy has been performed previously. All patients will take prophylactic loperamide with a stablished doses scheme during the firs cycle and on demand in subsequent cycles

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Progression-Free survival PFS6 (Efficacy)

  Proportion of patients alive and without progression (according to RECIST v1.1 criteria)

  at 24 weeks after first treatment administration

Secondary Outcomes (6)

• Clinical Benefit Rate at 6 months (CBR6)

  at 24 weeks after first treatment administration

• Overall Response rate (ORR)

  until objective tumor response, on average 8 months

• Progression free survival (PFS)

  until patients progression, on average 8 months

• Duration of response (DoR)

  from objective tumor response until patients progression, on average 8 months

• Time to response (TtR)

  from first treatment administration to the objective tumor response, on average 8 months

Study Arms (1)

Neratinib + endocrine therapy

EXPERIMENTAL

Neratinib plus Fulvestrant, Exemestane or Tamoxifen

Drug: Neratinib + endocrine therapy

Interventions

Neratinib + endocrine therapy DRUG

Neratinib plus Fulvestrant, Exemestane or Tamoxifen

Neratinib + endocrine therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \* Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of locally advanced or metastatic, histologically documented hormone receptor positive (ER and/or PR expression \>1%) and HER2- breast cancer by local testing, not amenable to surgical therapy will be enrolled in this study.
• HER2 negativity is defined as either of the following by local laboratory assessment: IHC 0, IHC 1+ or IHC2+/in situ hybridisation (ISH/FISH) negative as per American Society of Clinical Oncology (ASCO)-College of American Pathologists Guideline (CAP) guideline82.
• ER and/or PR positivity are defined as \>1% of cells expressing HR via IHC analysis as per ASCO-CAP guideline83.
• The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
• Postmenopausal, as defined by at least one of the following criteria:
• Age ≥60 years;
• Age \<60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression); and serum estradiol and FSH level within the laboratory's reference range for postmenopausal females;
• Documented bilateral oophorectomy,
• Medically confirmed ovarian failure OR
• Pre/perimenopausal, i.e., not meeting the criteria for being postmenopausal: Pre/perimenopausal women can be enrolled if amenable to be treated with the LHRH agonist. Patients must have commenced treatment with LHRH agonist at least 4 weeks prior to treatment start.
• \* No more than one prior line of chemotherapy for recurrent locally advanced or metastatic disease.
• Prior radiation therapy for metastatic disease is permitted. Subjects who were treated with radiation therapy may participate as long as at least 2 weeks have elapsed since the last dose of radiation therapy or have recovered from the effects of radiation before treatment start whichever is the latest.
• Disease refractory to aromatase inhibitors or fulvestrant or tamoxifen, defined as recurrence during or within 12 months after the end of adjuvant treatment or progression during or within 1 months after the end of treatment for advanced disease. Notes: Endocrine therapy do not have to be the last treatment prior to first treatment administration. Other prior anticancer endocrine therapy in combination with CDK 4/6 inhibitors or PI3K-pathway-targeted therapies (including PI3K, mTOR, PDK and AKT inhibitors) are also allowed. Patients who have received fulvestrant, exemestane and tamoxifen may be eligible
• \* Availability of formalin-fixed paraffin-embedded (FFPE) tumor block, taken less than 12 months before the start of the treatment during metastatic disease, if not available, confirmation by the Medical monitor will be required to include the patient in the study. A study-specific pathology report should be associated with the sample (every effort should be done to obtain the sample after the previous therapeutic regimen for advanced disease). The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for PAM50 analysis prior to enrollment. Patients whose tumor tissue is not evaluable for central testing are not eligible unless a biopsy from metastatic lesion is performed for this purpose.
• a) Acceptable samples include core needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions or biopsies from bone metastases.

You may not qualify if:

• Prior treatment with any ERBB2-directed TKI (eg, lapatinib, afatinib, dacomitinib, neratinib, tucatinib)
• Received prior therapy resulting in a cumulative epirubicin dose \>900 mg/m2 or cumulative doxorubicin dose \>450 mg/m2. If another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of 450 mg/m2 doxorubicin.
• Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina (symptomatic angina pectoris within the past 180 days that required the initiation of or increase in anti-anginal medication or other intervention), myocardial infarction within 12 months of enrollment, or ventricular arrhythmia (except for benign premature ventricular contractions).
• Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or Grade ≥2 National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events Version 5.0 \[CTCAE v.5.0\] diarrhea of any etiology at baseline).
• A WOCBP who has a positive urine pregnancy test within 72 hours prior to C1D1 (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Presence of any acute toxic effects from prior anti-cancer therapy or major surgical procedures to NCI CTCAE version 5.0 Grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator´s discretion). Note: Placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted.
• Uncontrolled pleural effusion, pericardial effusion, or ascites (Note: patients with indwelling catheters, such as PleurX® are allowed).
• Uncontrolled hypercalcemia (\>1.5 mmol/L \[\>6 mg/dL\] ionized calcium or serum calcium \[uncorrected for albumin\] \>3 mmol/L \[\>12 mg/dL\] or corrected serum calcium \>ULN) or clinically significant (symptomatic) hypercalcemia
• \* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
• Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and on a chronic stable dose of ≤ 2 mg total daily of dexamethasone (or equivalent) during the last 14 days.
• \* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
• \* Prior solid organ transplantation
• Has an active infection requiring systemic therapy.
• \* Has a known history of Human Immunodeficiency Virus (HIV).
• \* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.

Sponsors & Collaborators

• SOLTI Breast Cancer Research Group: lead

Study Sites (15)

IPO Lisboa

Lisbon, 1500-650, Portugal

Location

Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE

Porto, 4200-072, Portugal

Location

H. Clínico San Cecilio de Granada

Granada, Andalusia, Spain

Location

ICO Badalona

Badalona, Barcelona, Spain

Location

Hospital Clínic de Barcelona

Barcelona, Spain

Location

Hospital General de Catalunya

Barcelona, Spain

Location

Hospital Universitari Vall d' Hebron

Barcelona, Spain

Location

Hospital Marina Salud de Denia

Denia, 03700, Spain

Location

Complejo Hospitalario de Jaén

Jaén, 23007, Spain

Location

Hospital Universitari Arnau de Vilanova de Lleida

Lleida, 25198, Spain

Location

Hospital Universitario 12 de octubre

Madrid, Spain

Location

Hospital Universitario Ramon y Cajal

Madrid, Spain

Location

Hospital Son Llatzer

Palma de Mallorca, Spain

Location

Hospital Universitario Virgen del Rocio

Seville, Spain

Location

Hospital Virgen de Macarena

Seville, Spain

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

neratinib

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 29, 2020
• First Posted: July 7, 2020
• Study Start: July 23, 2020
• Primary Completion: November 29, 2021
• Study Completion: November 29, 2021
• Last Updated: October 25, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

PT (2); ES (13)